BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ITU512 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ITU512\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06546670-10298@assetmemo.bio
DTSTAMP:20261121T004105Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:ITU512: Phase 1/2 readout est. (NCT06546670)
DESCRIPTION:ITU512\, phase 1/2\, Sickle Cell Disease.\nStudy: A Phase I/II 
 Study of ITU512 in Healthy Participants and Patients With Sickle Cell Dise
 ase\nEstimated primary completion: 1 May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/itu512#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06546670
URL:https://assetmemo.bio/drug/itu512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
